Market closedNon-fractional
Cerus/CERS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Cerus
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Ticker
CERS
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Equipment and Supplies
Headquarters
Concord, United States
Employees
631
Website
www.cerus.com
Cerus Metrics
BasicAdvanced
$318M
Market cap
-
P/E ratio
-$0.17
EPS
1.30
Beta
-
Dividend rate
Price and volume
Market cap
$318M
Beta
1.3
Financial strength
Current ratio
2.414
Quick ratio
1.655
Long term debt to equity
156.084
Total debt to equity
200.556
Interest coverage (TTM)
-1.90%
Management effectiveness
Return on assets (TTM)
-6.32%
Return on equity (TTM)
-57.77%
Valuation
Price to revenue (TTM)
1.903
Price to book
6.43
Price to tangible book (TTM)
6.61
Price to free cash flow (TTM)
-8.452
Growth
Revenue change (TTM)
5.26%
Earnings per share change (TTM)
-33.00%
3-year revenue growth
19.20%
3-year earnings per share growth
-22.19%
What the Analysts think about Cerus
Analyst Ratings
Majority rating from 6 analysts.
Cerus Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$43M
-18.76%
Net income
-$9.6M
638.46%
Profit margin
-22.17%
812.35%
Cerus Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.07
-$0.04
-$0.01
-$0.05
-
Expected
-$0.06
-$0.05
-$0.02
-$0.05
-$0.04
Surprise
25.00%
-23.81%
-58.33%
7.14%
-
Cerus News
AllArticlesVideos
Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion
Business Wire·2 weeks ago
Cerus Corporation Celebrates World Blood Donor Day 2024
Business Wire·3 weeks ago
Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cerus stock?
Cerus (CERS) has a market cap of $318M as of July 06, 2024.
What is the P/E ratio for Cerus stock?
The price to earnings (P/E) ratio for Cerus (CERS) stock is 0 as of July 06, 2024.
Does Cerus stock pay dividends?
No, Cerus (CERS) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Cerus dividend payment date?
Cerus (CERS) stock does not pay dividends to its shareholders.
What is the beta indicator for Cerus?
Cerus (CERS) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Cerus stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.